Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Drug Discovery
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 369269
License Grant
Licensor grants an exclusive right and license, including the right to grant sublicense rights, under Licensed Technology to make, have made, use, offer to sell, sell, and import Licensed Products in the Territory.
License Property
The Compound shall mean 1-[5-[(aminoiminomethyl)arnino]-1-oxo-2-[[(1,2,3,4- tetrah ydro-3-methyl-8-qu inolinyl )sulfon y 1] amino ]penty l]-4-meth yl-2-piperidinecarboxylic acid, monohydrate, commonly known as argatroban.
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.
Field of Use
Thrombin inhibitors are used to prevent Arterial and venous thrombosis (blood clot blocks in arteries/veins) Deep vein thrombosis (blood clot in a deep vein, usually in the legs)
IPSCIO Record ID: 369270
License Grant
This amendment is a grant back of certain technology. In connection with such license grant, the Parties desire to amend certain sections of the Agreement to reflect such license grant and the development and commercialization.
Licensor grants an exclusive right and license, including the right to grant sublicense rights, under Licensor Licensed Technology to make, have made, use, offer to sell, sell, and import Licensed Products in the Territory.
License Property
The Compound shall mean 1-[5-[(aminoiminomethyl)arnino]-1-oxo-2-[[(1,2,3,4- tetrah ydro-3-methyl-8-qu inolinyl )sulfon y 1] amino ]penty l]-4-meth yl-2-piperidinecarboxylic acid, monohydrate, commonly known as argatroban.
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.
Field of Use
The field of use is the Pharmaceutical industry.
IPSCIO Record ID: 314347
License Grant
Subject to the exercise of the Option by the Licensee, Licensor hereby grants the Licensee, an exclusive irrevocable for the License Term, transferable (subject to the terms of this Agreement herein), royalty bearing license, for the License Term, to research, develop, perform, produce, make, have made, use, market, sell, lease, dispose, copy, modify, lease, distribute, display, bundle, sub-license, import, export and commercialize the Licensed Products and/or Compounds in the Territory, including, without limitation, through the grant of Right.
License Property
Licensed Product shall mean the Compounds, or any part thereof, and/or any new Intellectual Property Rights developed made, conceived or created (including through third party contractors) containing any inventions, innovations and other improvements, resulting from the Compounds or any part thereof and/or are deriving from and/or containing the Compounds and/or any part thereof.
Compound shall mean the Thrombin Inhibitor compounds with potential therapeutic value.
Intellectual Property Rights means any and all intellectual property rights, including without limitation patents, patent applications, any copyrights and registrations and applications for registration thereof, computer software, programs, data and documentation, technology, trade secrets and confidential business information, whether patentable or non-patentable and whether or not reduced to practice, know-how, designs, prototypes, laboratory protocols, enhancements, improvements, works-in-progress, research and development information, and other proprietary rights relating to any of the foregoing (including without limitation remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions).
Field of Use
Field means antithrombotics, including anticoagulants, antiplatelets and thrombolytics classes and specifically Thrombin inhibitors, for treatment of thrombosis and thromboembolic diseases.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system.
IPSCIO Record ID: 243476
License Grant
This letter details the sales terms of the enoxoparin sodium injection product.
Pursuant to a separate agreement relating to the development and commercialization of enoxaparin, and, to characterize the generic enoxaparin for the purpose of obtaining regulatory approval.
Thereafter, Licensee incorporated the technology of the University into release testing of unfractionated heparin used in the manufacture of generic enoxaparin.
License Property
The University and Licensee hereby acknowledge that the enoxaparin product approved by the FDA in July 2010 constitutes a Licensed Product.
Enoxaparin is an anticoagulant that helps prevent the formation of blood clots.
Field of Use
Enoxaparin sodium is an anticoagulant medication. It is used to treat and prevent deep vein thrombosis and pulmonary embolism including during pregnancy and following certain types of surgery.
IPSCIO Record ID: 27689
License Grant
The Licensor and the Swiss and US Licensee entered into a letter agreement amending the Collaboration and License Agreement relating to, among other things, the development and commercialization of Enoxaparin Sodium Injection.
License Property
Enoxaparin Sodium Injection, a generic version of Lovenox, an anti-coagulant drug used for multiple indications including prevention of deep vein thrombosis, a potentially deadly blood clotting condition.
Field of Use
The Licensee specializes in generic pharma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
